PT Merck Tbk

Jakarta Stock Exchange MERK.JK

PT Merck Tbk Price to Sales Ratio (P/S) on January 14, 2025: 1.54

PT Merck Tbk Price to Sales Ratio (P/S) is 1.54 on January 14, 2025, a -19.39% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

PT Merck Tbk 52-week high Price to Sales Ratio (P/S) is 1.91 on January 16, 2024, which is 24.06% above the current Price to Sales Ratio (P/S).
PT Merck Tbk 52-week low Price to Sales Ratio (P/S) is 1.50 on January 07, 2025, which is -2.55% below the current Price to Sales Ratio (P/S).
PT Merck Tbk average Price to Sales Ratio (P/S) for the last 52 weeks is 1.73.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Jakarta Stock Exchange: MERK.JK

PT Merck Tbk

CEO	Ms. Evie Yulin
IPO Date	May 3, 2002
Location	Indonesia
Headquarters	Jl. TB Simatupang No. 8
Employees	377
Sector	Health Care
Industries Pharmaceuticals

Description

PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. It operates through three segments: Biopharma, Consumer Health, and Others. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in discovering, developing, manufacturing, and marketing pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders comprising hyperthyroidism and hypothyroidism. In addition, it leases and manages properties. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is headquartered in East Jakarta, Indonesia. PT Merck Tbk is a subsidiary of Merck Holding GmbH.

Key trends

Past 5 years